Skip to content
‹ Back to IndustriesSciences

Terminator-Inspired Shape-Shifting Robot Becomes Reality. What Use Cases Does It Have in Manufacturing?

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end. The new robot was…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · Liquid Metal RobotMagnetoactive Phase Transitional MatterManufacturingMptm
Share

Key takeaways

01

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist.

02

This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers.

03

However, that’s where the similarities end.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Thirty-two years after the release of Terminator 2, groundbreaking research in phase-shifting materials has made it possible for a real-life shape-shifting robot to exist. This new robot has the same ability as the T-1000 to transform into a liquid shape and pass through barriers. However, that’s where the similarities end.

The new robot was developed by a team from The Chinese University of Hong Kong under the direction of Dr. Chengfeng Pan. It is made up of a newly developed phase-shifting material researchers call “magnetoactive liquid-solid phase transitional matter,” or MPTM. Magnetic particles embedded in the material of the robot allow users to control it. This means it can be heated and cooled on demand using an alternating magnetic field to melt it into a liquid and then solidify it again.

This research is just one of the many advancements shaping the future of robotics and its use cases. Scientists are hoping that this discovery will one day be of use in a variety of fields, including medicine and assembly lines. MPTM could make it easier to solder and screw parts in hard-to-reach places, for example, but that’s hopefully just scratching the surface of its utility.

How can the manufacturing industry benefit from a shape-shifting robot? And are there any manufacturing applications where a flexible structure can make a huge difference? We reached out to Rhonda DiBachi, CEO of HeyScottie, for her expert opinion and analysis on this T-1000 tech. Rhonda has been implementing manufacturing techniques for companies since the 1980s and founded numerous startups for tech and manufacturing. 

Rhonda’s Thoughts:

“I don’t know of any manufacturing applications for this new material called MPTM or Magnetoactive Phase Transitional Matter. It’s early days. I do know of some applications of a similar kind of material called a shape memory alloy. That’s metals that change their shape depending upon changes in temperature and pressure.

I know that those are used in pneumatic and flow control systems to change valves. That’s interesting. An interesting application for this new kind of material, MPTM, I would think would be 3D printing, metal 3D printing. You could create struts using this material and when you’re building up the part you could use the struts, they would be structural.

But then when you’re done building up the part, you don’t need the struts anymore. And, if you could flip a switch and make them change their shape, they might be able to just slither out, making removal quite a bit easier than it is right now. Could be interesting.”

Article written by Sonia Gossai.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte's December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own financial outlook but only 41% optimistic about the global economy, the mood the program is built for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512